PharmD - University of Texas


Dr. Mosley received a B.S. in Biochemical/Biophysical Science from the University of Houston in 2006, then worked for three years in a core pharmacology lab as an analytical chemist for MD Anderson Cancer Center in Houston, TX. He received his PharmD degree from the University of Texas in 2013, then took a position as a pharmacist with MD Anderson Cancer Center. He completed a postdoctoral research fellowship in Gainesville, FL at the University of Florida College of Pharmacy in the Center for Pharmacogenomics where his research focused on pharmacogenomics implementation, which incorporates genetic information with other clinical factors to optimize drug selection. In June, 2018 he joined the USC faculty as assistant professor of clinical pharmacy. Beginning in June, 2019, Dr. Mosley and collaborators at LAC+USC and Keck School of Medicine of USC will begin a clinical study to determine the utility of clinical genotyping to guide antiplatelet therapy in patients with acute coronary syndromes (ACS), post percutaneous coronary intervention (PCI). This research aims to define the utility of recent technological advances to individualize therapy for minority patients with ACS/PCI treated with dual antiplatelet therapy (DAPT), who are underrepresented in current personalized medicine studies.

NIH Funding Acknowledgment: Important - All publications resulting from the utilization of SC CTSI resources are required to credit the SC CTSI grant by including the NIH funding acknowledgment and must comply with the NIH Public Access Policy.